Across TCGA pan-cancer cohorts, PRELID3BP1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PRELID3BP1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where PRELID3BP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRELID3BP1 is over-expressed in tumor, although a few such as READ show the opposite, repressed pattern.

COAD, UCEC, and READ are the cancer types where PRELID3BP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRELID3BP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	All	+0.241	.008	6	view →
UCEC	All	IV	+0.355	.015	2	view →
READ	All	III,IV	−0.155	.025	2	view →
BLCA	All	All	+0.143	.035	2	view →
LUSC	All	All	+0.065	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PRELID3BP1 RNA expression & survival · all PRELID3BP1 data types